A long-acting amylin analog peptide studied in models of satiety signaling, food intake, and body weight, including combination research with GLP-1 agonists.
🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.
Cagrilintide is a synthetic, long-acting analog of amylin (islet amyloid polypeptide), a hormone co-secreted with insulin by pancreatic beta cells. It is engineered for extended duration and acts as an agonist at amylin and calcitonin receptors.
It is studied both on its own and in combination with GLP-1 receptor agonists such as semaglutide (the CagriSema research combination).
Cagrilintide activates amylin and calcitonin receptor complexes, which in preclinical models influence satiety signaling and gastric emptying via hindbrain and hypothalamic circuits.
Its amylin-based mechanism is investigated as complementary to GLP-1 receptor agonism in combined metabolic research.
Satiety signaling — studied in models of amylin/calcitonin receptor activation and food intake [1].
Body weight models — investigated in phase 2 obesity trials measuring body weight change [1].
Combination pharmacology — examined with semaglutide (CagriSema) for additive metabolic effects [2].
Gastric physiology — evaluated for effects on gastric emptying [1].
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.
In a phase 2 trial, adults with obesity received cagrilintide across a range of study doses and investigators measured body weight change over 26 weeks [1]. In combination research, participants received cagrilintide together with semaglutide and researchers measured body weight and glycemic markers [2].
Preclinical pharmacology studies characterized receptor binding at amylin and calcitonin receptors [1].
Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.
SemaglutideSynergistic
Studied together as CagriSema, combining amylin and GLP-1 pharmacology in obesity research.
TirzepatideNeutral
Distinct incretin mechanism; combined use not established in mainstream literature.
InsulinCaution
Amylin analogs are studied alongside insulin in glucose-handling research designs.
RetatrutideNeutral
Separate receptor targets; compared rather than combined.
Citations below are retrieved automatically from PubMed (NIH / U.S. National Library of Medicine) for the search term “Cagrilintide”, newest first. They are listed as literature references for research purposes only. K4 Elite does not summarise, interpret or endorse their findings.
A long-acting synthetic analog of the hormone amylin, acting at amylin and calcitonin receptors.
What is CagriSema?
A research combination of cagrilintide and semaglutide studied in obesity and metabolic trials.
What research areas apply?
Satiety signaling, body weight in obesity models, gastric emptying, and combination pharmacology with GLP-1 agonists.
Is this material for human use?
No. It is supplied for in-vitro and laboratory research use only, not for human or veterinary use.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.
K4 Elite